scholarly article | Q13442814 |
P50 | author | Renato Franco | Q37376215 |
Antonio Rossi | Q37829909 | ||
Michele Caraglia | Q38321049 | ||
Ettore Novellino | Q38359645 | ||
Alessandro Sgambato | Q39493156 | ||
Alfredo Budillon | Q40122753 | ||
Mario Migaldi | Q51621448 | ||
Agnese Molinari | Q55779035 | ||
Giuseppina Bozzuto | Q58896092 | ||
Gerardo Botti | Q62091425 | ||
P2093 | author name string | Paolo Grieco | |
Laura Toccacieli | |||
Achille Cittadini | |||
Monica Marra | |||
Luigi Marra | |||
Stefano Striano | |||
Silvia Zappavigna | |||
Luigi Gallo | |||
P2860 | cites work | Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 | Q22010575 |
Differential regulation of cell motility and invasion by FAK | Q24673170 | ||
Genomic analysis of metastasis reveals an essential role for RhoC | Q28144278 | ||
The focal adhesion kinase--a regulator of cell migration and invasion | Q28202601 | ||
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis | Q29615193 | ||
Spatiotemporal dynamics of RhoA activity in migrating cells | Q29618433 | ||
MMP inhibition in prostate cancer | Q33692934 | ||
Treatment decisions for localized prostate cancer: asking men what's important | Q33843865 | ||
Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease | Q34204725 | ||
Urotensin-II receptor peptide agonists | Q35821444 | ||
Molecular markers of prostate cancer outcome | Q36088809 | ||
20-year outcomes following conservative management of clinically localized prostate cancer | Q36115855 | ||
Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion | Q37374521 | ||
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells | Q39837442 | ||
The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? | Q40066264 | ||
Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines | Q40341061 | ||
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial | Q40352912 | ||
Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. | Q40659791 | ||
Expression of endothelin-1 and endothelin receptors in cultured human glioblastoma cells | Q40842569 | ||
Effect of endothelin-1 as growth factor on a human glioma cell line; its characteristic promotion of DNA synthesis | Q41586620 | ||
Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta | Q41819007 | ||
Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats | Q43264253 | ||
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. | Q44381567 | ||
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. | Q51823933 | ||
Architecture of the Human Urotensin II Receptor: Comparison of the Binding Domains of Peptide and Non-Peptide Urotensin II Agonists | Q58855793 | ||
P433 | issue | 1 | |
P921 | main subject | adenocarcinoma | Q356033 |
prostate adenocarcinoma | Q18555107 | ||
P304 | page(s) | 341-353 | |
P577 | publication date | 2011-01-01 | |
P1433 | published in | Journal of Cellular Biochemistry | Q6294917 |
P1476 | title | Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. | |
P478 | volume | 112 |
Q42139903 | A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands |
Q36800401 | Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER |
Q39313143 | Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis. |
Q90598614 | Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours |
Q37582059 | Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma |
Q88874237 | Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly? |
Q37740977 | Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297. |
Q48372089 | Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. |
Q33599835 | The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features |
Q34066190 | The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer |
Q41613067 | Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients |
Q33772333 | Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion |
Q38588658 | Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer |
Q39039151 | Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. |
Q92591557 | Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells |
Search more.